다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
영국
LSE
Aim Immunotech Inc (0A4Y)
Aim Immunotech Inc (0A4Y) 뉴스

0A4Y

Aim Immunotech (0A4Y)

Aim Immunotech Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0A4Y

1

일자	시간	출처	헤드라인	심볼	기업
2024/05/09	21:50	UK Regulatory	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	LSE:0A4Y	Aim Immunotech Inc
2024/05/06	21:30	UK Regulatory	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	LSE:0A4Y	Aim Immunotech Inc
2024/04/29	21:55	UK Regulatory	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	LSE:0A4Y	Aim Immunotech Inc
2024/04/10	21:21	UK Regulatory	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	LSE:0A4Y	Aim Immunotech Inc
2024/04/02	20:30	UK Regulatory	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	LSE:0A4Y	Aim Immunotech Inc
2024/03/26	22:05	UK Regulatory	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	LSE:0A4Y	Aim Immunotech Inc
2024/03/25	22:05	UK Regulatory	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	LSE:0A4Y	Aim Immunotech Inc
2024/03/07	22:45	UK Regulatory	AIM ImmunoTech Announces Launch of CEO Corner Platform	LSE:0A4Y	Aim Immunotech Inc
2024/02/29	22:45	UK Regulatory	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update	LSE:0A4Y	Aim Immunotech Inc
2024/02/14	22:55	UK Regulatory	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer	LSE:0A4Y	Aim Immunotech Inc

검색 관련기사 보기:LSE:0A4Y

1

Invesco QQQ Trust Series 1

US Dollar vs Sterling

Energy Select Sector SPDR

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관